Inclisiran Sodium CAS 1639324-58-5

Inclisiran sodium CAS 1639324-58-5, is a first-in-class siRNA developed by Alnylam Pharmaceuticals Inc. It is a PCSK9 inhibitor. Currently, the highest development stage of this drug is approval for marketing, which is used to treat hypercholesterolemia, dyslipidemia, carotid artery disease, heterozygous familial hypercholesterolemia and atherosclerosis.
On December 9, 2020, Inxlan sodium was approved by the European Medicines Agency (EMA) and is marketed by Novartis Europharm Ltd under the trade name Leqvio®. (EMEA/H/C/005333).